Ocular side effects of the lipid-lowering drug simvastatin? A one year follow-up
- PMID: 2488025
Ocular side effects of the lipid-lowering drug simvastatin? A one year follow-up
Abstract
Simvastatin, a new HMG-CoA-reductase inhibitor, was administered to 27 patients for a period of one year. This drug caused a sustained decrease in total plasma- and LDL-cholesterol. No development of cataracts could be observed during this one year follow-up.
MeSH terms
Substances
LinkOut - more resources
Medical